Ionis Pharma – AstraZeneca Antisense Medicine Met Its Primary, Secondary Goals To Lower Cholesterol
Ionis Pharmaceuticals Inc (NASDAQ: IONS) and its partner, AstraZeneca Plc (NASDAQ: AZN), have
SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Lowers Price Target to $26
SVB Leerink analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and lowers the price target from $29 to $26.
Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints
Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have
Why Cramer Likes Ferguson And Stanley Black & Decker
On CNBC’s "Mad Money Lightning Round," Jim Cramer said ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) is a "momentum-driven stock" whose momentum he believes has peaked.
Ionis Announced Wednesday, Publication of Positive Phase 2 Data for Donidalorsen in New England Journal of Medicine
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced the publication of positive Phase 2 data for donidalorsen (formerly IONIS-PKK-LRx) in the New England Journal of Medicine (NEJM) available at NEJM.org.
Benzinga’s Daily Brief On Trending Tickers For March 2, 2022: VanEck Russia ETF, AMC Entertainment, SoFi Technologies And More
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks.
The data on the trending tickers is compiled from a list of most-discussed tickers on the popular Reddit forum WallStreetBets.
Guggenheim Initiates Coverage On Ionis Pharmaceuticals with Buy Rating, Announces Price Target of $64
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy rating and announces Price Target of $64.
Citigroup Initiates Coverage On Ionis Pharmaceuticals with Sell Rating, Announces Price Target of $26
Citigroup analyst David Lebowitz initiates coverage on Ionis Pharmaceuticals (NASDAQ:IONS) with a Sell rating and announces Price Target of $26.